MCID: LYM031
MIFTS: 56

Lymphocytic Leukemia

Categories: Blood diseases, Bone diseases, Cancer diseases, Immune diseases, Rare diseases

Aliases & Classifications for Lymphocytic Leukemia

MalaCards integrated aliases for Lymphocytic Leukemia:

Name: Lymphocytic Leukemia 12 15
Lymphoblastic Leukemia 12 15
Leukaemia Lymphocytic 55
Leukemia, Lymphoid 44
Lymphoid Leukemia 17

Classifications:



External Ids:

Disease Ontology 12 DOID:1037
ICD9CM 35 204 204.9
MeSH 44 D007945
NCIt 50 C7539
SNOMED-CT 68 32280000 93170002
ICD10 33 C91 C91.9 C91.90
UMLS 72 C0023448

Summaries for Lymphocytic Leukemia

Disease Ontology : 12 A leukemia that has material basis in lymphoblasts (immature white blood cells).

MalaCards based summary : Lymphocytic Leukemia, also known as lymphoblastic leukemia, is related to leukemia, chronic lymphocytic and cll/sll. An important gene associated with Lymphocytic Leukemia is DLEU2 (Deleted In Lymphocytic Leukemia 2), and among its related pathways/superpathways are MicroRNAs in cancer and Thyroid hormone signaling pathway. The drugs alemtuzumab and Tacrolimus have been mentioned in the context of this disorder. Affiliated tissues include b cells, t cells and bone, and related phenotypes are hematopoietic system and immune system

Related Diseases for Lymphocytic Leukemia

Diseases in the Lymphocytic Leukemia family:

Leukemia, Chronic Lymphocytic 2 Leukemia, Chronic Lymphocytic
Leukemia, Chronic Lymphocytic 1 Leukemia, Chronic Lymphocytic 3
Leukemia, Chronic Lymphocytic 4 Leukemia, Chronic Lymphocytic 5
Adult Acute Lymphocytic Leukemia

Diseases related to Lymphocytic Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1613)
# Related Disease Score Top Affiliating Genes
1 leukemia, chronic lymphocytic 34.6 ZAP70 TRIM13 TP53 PEG10 NOTCH1 CD38
2 cll/sll 34.2 ZAP70 TP53 MME CD38 ATM
3 leukemia, chronic lymphocytic 2 33.8 TP53 DLEU2 DLEU1
4 leukemia, acute lymphoblastic 3 33.7 TP53 PEG10 MME
5 richter's syndrome 33.5 TP53 NOTCH1 MYC CD38 ATM
6 precursor t-cell acute lymphoblastic leukemia 33.4 TAL1 NOTCH1 MYC
7 prolymphocytic leukemia 33.4 ZAP70 MYC CD38 ATM
8 acute t cell leukemia 33.3 TAL2 TAL1 NOTCH1
9 leukemia 32.9 TP53 TAL2 TAL1 NOTCH1 HOTAIR CLLU1
10 leukemia, acute myeloid 32.7 TP53 MYC MME HOTAIR CD38
11 mantle cell lymphoma 31.7 TP53 MYC MME BTK ATM
12 lymphoma, non-hodgkin, familial 31.7 TP53 NOTCH1 MYC MME CD38 ATM
13 t-cell leukemia 31.6 TP53 TAL1 NOTCH1 MYC ATM
14 lymphoblastic lymphoma 31.3 TAL1 NOTCH1 MME
15 myeloma, multiple 31.2 TP53 MYC MME HOTAIR CD38
16 diffuse large b-cell lymphoma 31.1 TP53 PEG10 MYC MME HOTAIR
17 b cell prolymphocytic leukemia 31.1 ZAP70 TP53 MYC CD38
18 mature b-cell neoplasm 31.1 TP53 MYC MME CD38
19 acquired immunodeficiency syndrome 31.1 TP53 MYC CD38
20 plasmablastic lymphoma 31.0 NOTCH1 MYC CD38
21 hematologic cancer 30.7 ZAP70 TP53 NOTCH1 MYC MME CD38
22 small cell cancer of the lung 29.1 TP53 MYC HOTAIR
23 b-cell childhood acute lymphoblastic leukemia 12.8
24 t-cell large granular lymphocyte leukemia 12.7
25 childhood acute lymphocytic leukemia 12.7
26 lymphoblastic leukemia, acute, with lymphomatous features 12.6
27 adult acute lymphocytic leukemia 12.6
28 large granular lymphocyte leukemia 12.6
29 t-cell adult acute lymphocytic leukemia 12.5
30 leukemia, acute lymphoblastic 12.4
31 b-cell adult acute lymphocytic leukemia 12.4
32 postgerminal center chronic lymphocytic leukemia/small lymphocytic lymphoma 12.3
33 pregerminal center chronic lymphocytic leukemia/small lymphocytic lymphoma 12.3
34 acute lymphoblastic leukemia congenital sporadic aniridia 12.3
35 t-cell childhood acute lymphocytic leukemia 12.3
36 t-cell prolymphocytic leukemia 12.2
37 leukemia, b-cell, chronic 12.1
38 precursor lymphoblastic lymphoma/leukemia 11.9
39 hairy cell leukemia 11.8
40 natural killer cell leukemia 11.8
41 myeloid leukemia 11.7
42 precursor b lymphoblastic lymphoma/leukemia 11.7
43 medulloblastoma 11.7
44 acute leukemia 11.6
45 ataxia-telangiectasia 11.6
46 immunotactoid glomerulopathy 11.5
47 pdgfra-associated chronic eosinophilic leukemia 11.3
48 childhood precursor t-lymphoblastic lymphoma/leukemia 11.3
49 immunotactoid or fibrillary glomerulopathy 11.2
50 prostate cancer 11.0

Graphical network of the top 20 diseases related to Lymphocytic Leukemia:



Diseases related to Lymphocytic Leukemia

Symptoms & Phenotypes for Lymphocytic Leukemia

MGI Mouse Phenotypes related to Lymphocytic Leukemia:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.85 ATM BTK CD38 MYC NOTCH1 SETDB2
2 immune system MP:0005387 9.65 ATM BTK CD38 MME MYC NOTCH1
3 integument MP:0010771 9.23 ATM BTK MME MYC NOTCH1 TAL1

Drugs & Therapeutics for Lymphocytic Leukemia

Drugs for Lymphocytic Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 711)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
alemtuzumab Approved, Investigational Phase 4 216503-57-0
2
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
3
Micafungin Approved, Investigational Phase 4 235114-32-6 3081921 477468
4
Posaconazole Approved, Investigational, Vet_approved Phase 4 171228-49-2 147912
5
Valganciclovir Approved, Investigational Phase 4 175865-60-8 64147
6
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
7
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
8
Promethazine Approved, Investigational Phase 4 60-87-7 4927
9
Acetaminophen Approved Phase 4 103-90-2 1983
10
Diphenhydramine Approved, Investigational Phase 4 58-73-1, 147-24-0 3100
11
Oprelvekin Approved, Investigational Phase 4 145941-26-0
12
Pancrelipase Approved, Investigational Phase 4 53608-75-6
13
Heparin Approved, Investigational Phase 4 9005-49-6 46507594 772
14
Idarubicin Approved Phase 4 58957-92-9 42890
15
Decitabine Approved, Investigational Phase 4 2353-33-5 451668
16
Metformin Approved Phase 4 657-24-9 4091 14219
17
Epirubicin Approved Phase 4 56420-45-2 41867
18
Iron Approved, Experimental Phase 4 15438-31-0, 7439-89-6 23925 27284
19
Nicotine Approved Phase 4 54-11-5 942 89594
20
Morphine Approved, Investigational Phase 4 57-27-2 5288826
21
Teniposide Approved Phase 4 29767-20-2 34698
22
Chlorambucil Approved Phase 4 305-03-3 2708
23
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 6221 5280795
24
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
25
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
26
Calcifediol Approved, Nutraceutical Phase 4 19356-17-3 6433735 5283731
27 Imatinib Mesylate Phase 4 220127-57-1 123596
28 Vaccines Phase 4
29
Ethylene Phase 4 74-85-1 6325
30 Cyclosporins Phase 4
31 Antilymphocyte Serum Phase 4
32 Hydrocortisone 17-butyrate 21-propionate Phase 4
33 Hydrocortisone hemisuccinate Phase 4
34 pancreatin Phase 4
35 calcium heparin Phase 4
36 Thymoglobulin Phase 4
37 Hypoglycemic Agents Phase 4
38 Liver Extracts Phase 4
39 Iron Chelating Agents Phase 4
40 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
41 Calciferol Phase 4
42 Vitamin D2 Phase 4
43 Ergocalciferols Phase 4
44 Hydroxycholecalciferols Phase 4
45 Neurotransmitter Agents Phase 4
46 Hematinics Phase 4
47 Epoetin alfa Phase 4 113427-24-0
48 Neurotransmitter Uptake Inhibitors Phase 4
49 Adrenergic Agents Phase 4
50 Atomoxetine Hydrochloride Phase 4

Interventional clinical trials:

(show top 50) (show all 3054)
# Name Status NCT ID Phase Drugs
1 Multicenter Study To Optimize Treatment in Elderly Patients (> 55 Years, No Upper Age Limit) With Acute Lymphoblastic Leukemia (GMALL Elderly 1/2003)(Amend 2) Unknown status NCT00198978 Phase 4 Cyclophosphamide;Dexamethasone / Prednisolone;Cytarabine;Idarubicin;Granulocyte-Colony-Stimulating Factor;Mercaptopurine;Methotrexate;Rituximab;HDARAC;Vincristine;Depocyte;Asparaginase
2 German Multicenter Study for Treatment Optimisation in Acute Lymphoblastic Leukemia in Adults and Adolescents Above 15 Years (Amend 3) (GMALL 07/2003) Unknown status NCT00198991 Phase 4 Cyclophosphamide;Dexamethasone;Vincristine;daunorubicin;Asparaginase;Methotrexate;Cytarabine;Mercaptopurine;G-CSF;Vindesine;VP16;Prednisolone;Adriamycin;Thioguanine;VM26;Idarubicin;Fludarabine;Cladribine
3 A Multicenter, Open-Label Study of Nipent, Cytoxan and Rituxan in Patients With Previously Untreated or Treated Chronic Lymphocytic Leukemia. Unknown status NCT00131313 Phase 4 Nipent, Cytoxan, Rituxan
4 Philadelphia -Negative High-risk Children Acute Lymphoblastic Leukemia(ALL) Treatment:Induction Therapy:Vincristine(V),Idarubicin(I),L-asparaginase(L),Dexamethasone(D);Consolidation:V+Daunorubicin(D)+L+D, Methotrexate,Cytarabine Unknown status NCT01990807 Phase 4 Idarubicin(IDA)
5 PEG-asparaginase During Two Treatment Courses in the Treatment of Childhood Acute Lymphoblastic Leukemia Unknown status NCT00192673 Phase 4 PEG-asparaginase
6 Ma-Spore ALL 2010 Study Unknown status NCT02894645 Phase 4 Prednisolone;Dexamethasone;L-Asparaginase;Vincristine;Methotrexate;Daunorubicin;Doxorubicin;Cyclophosphamide;Cytarabine;6-Mercaptopurine;Thioguanine;Fludarabine;Imatinib
7 The Combination of Lower Dosage of Chemotherapy With Tyrosine Kinase Inhibitor to Treat Newly Diagnosed ph+ Acute Lymphoblastic Leukemia Patients Unknown status NCT02690922 Phase 4 Dasatinib;prednisone;dexamethasone;methotrexate
8 Medical Research Council Working Party on Leukaemia in Children UK National Acute Lymphoblastic Leukaemia (ALL) Trial: UKALL 2003 Unknown status NCT00222612 Phase 4 Standard childhood UK ALL protocol;Intensified treatment including Capizzi maintenance
9 Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults Unknown status NCT00797810 Phase 4 Rituximab
10 Clinical Study of GD-2008 ALL Protocol for Childhood Acute Lymphoblastic Leukemia in Guangdong Province Unknown status NCT00846703 Phase 4 6-mercaptopurine, Methotrexate;6-mercaptopurine, Methotrexate, Vincristine, Dexamethasone
11 An Open-label,Multi-center,Prospective Study of Idarubicin and Etoposide Intensified Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation for Adult Acute Lymphoblastic Leukemia Unknown status NCT01873807 Phase 4 IDA;CTX;VP-16
12 Evaluation of the Immune Response After Vaccination Against Hepatitis B in Patients With Indolent Lymphoproliferative Disorders With no Treatment. Unknown status NCT01698866 Phase 4
13 ASSESSMENT OF GH-IGF1 AXIS AND TO STUDY RESPONSE TO GH THERAPY IN CHILDREN WITH CML IN REMISSION HAVING GH DEFICIENCY Unknown status NCT01901666 Phase 4 Growth Hormone
14 1-Year Longitudinal Follow-up Study of Serologic Responses to 7-valent Pneumococcal Conjugated Vaccination and Opsonophagocytic Activities for Streptococcus Pneumoniae Among Patients With Human Immunodeficiency Virus Infection Unknown status NCT00885625 Phase 4
15 A Single-arm, International, Multi-center Trial Investigating the Efficacy and Safety of Ofatumumab Retreatment and Maintenance in CLL Patients Who Progressed Following Response or Stable Disease After Ofatumumab Treatment in Hx-CD20-406 Completed NCT00802737 Phase 4 Ofatumumab
16 The Study on the Pharmacokinetics of Pegylated Recombinant Human Granulocyte Stimulating Factor(PEG-rhG-CSF) in Children and Adolescents Completed NCT02953730 Phase 4 PEG-rhG-CSF
17 Pilot Study for Treatment of Elderly Patients (>65 Years) With Acute Lymphoblastic Leukemia Completed NCT00199095 Phase 4 Adriamycin;Cyclophosphamide;Cytarabine;Dexamethasone;Idarubicin;Ifosfamide;Methotrexate;Mercaptopurine;VM26;Vincristine
18 Multicenter Trial for Treatment of Acute Lymphoblastic Leukemia in Adults (05/93) Completed NCT00199069 Phase 4 Asparaginase;Vincristine;Daunorubicin, Adriamycin;Cyclophosphamide;Ifosfamide;Cytarabine;Mitoxantrone;Methotrexate;6-Mercaptopurine;6-Thioguanine;VM26;Dexamethasone / Prednisolone
19 A Randomized Open-Label Trial of Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome Completed NCT01200355 Phase 4 micafungin;posaconazole
20 German Multicenter Trial for Treatment Optimisation in Acute Lymphoblastic Leukemia in Adults and Adolescents Above 15 Years With Rituximab for Improvement of Prognosis in CD20 Positive Standard Risk ALL (Amend 2) Completed NCT00199004 Phase 4 Cyclophosphamide;Dexamethasone / Prednisolone;Vincristine;Daunorubicin;Asparaginase;Methotrexate;Cytarabine;Mercaptopurine;G-CSF;Vindesine;VP16;Adriamycin;Thioguanine;VM26;Rituximab
21 Multicenter Trial for Treatment of Acute Lymphocytic Leukemia in Adults (Pilot Study 06/99) Completed NCT00199056 Phase 4 Dexamethasone / Prednisolone;Cyclophosphamide;Methotrexate;Vincristine / Vindesine;Daunorubicin;Asparaginase;G-CSF;Cytarabine;6-Mercaptopurine;VP16;Adriamycin;Thioguanine;VM26;Idarubicin;Fludarabine;Ifosfamide
22 A Multicenter Study to Confirm the Efficacy and Safety of Fludara i.v. (Fludarabine Phosphate, SH L 573), Administered in 6 Treatment Cycles (1 Treatment Cycle: 5-consecutive Day Dosing, Followed by an Observation Period of 23 Days) in Untreated Chronic Lymphocytic Leukemia Patients With Anemia and/or Thrombocytopenia Completed NCT00220311 Phase 4 Fludarabine Phosphate (Fludara)
23 The Duration of Humoral Immunity and the Memory Cell Function After Vaccination With 7-valent Pneumococcal Conjugate Vaccine in CLL Completed NCT00919321 Phase 4
24 Treatment of Chronic Lymphocytic Leukemia With the Use of an Antiviral Compound - a Proof of Principle Study Completed NCT01255644 Phase 4 Valganciclovir
25 A Randomized Study to Assess the Effect on Response Rate of MabThera (Rituximab) Added to a Standard Chemotherapy, Bendamustine or Chlorambucil, in Patients With Chronic Lymphocytic Leukemia Completed NCT01056510 Phase 4 bendamustine;chlorambucil;rituximab [MabThera/Rituxan]
26 Pulses of Vincristine and Dexamethasone During Maintenance in BFM Protocols for Children With Intermediate-Risk Acute Lymphoblastic Leukemia Completed NCT00411541 Phase 4 vincristine;dexamethasone
27 Effect of Treatment Using rhIL-11 in Patients With Thrombocytopenia After Chemotherapy for Childhood Acute Lymphoblastic Leukemia Completed NCT02314273 Phase 4 rhIL-11
28 Prospective Study of Rituximab Combined With Chemotherapy for CD20+ Adult Acute Lymphoblastic Leukemia Completed NCT01358253 Phase 4 Cyclophosphamide;Doxorubicin;Vincristine;Dexamethasone;Cytarabine;Methotrexate;Rituximab;6-Mercaptopurine;Prednisone;L-asparaginase
29 Learning Impairments Among Survivors of Childhood Cancer Completed NCT00576472 Phase 4 Methylphenidate
30 Evaluation of Allogeneic Marrow Transplants Depleted of T-Cells by CD34+ Selection in Patients Undergoing Transplantation With an Unrelated Matched or 1 Antigen Mismatched Donor or a 1 Antigen Mismatched Related Donor Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
31 ALL-REZ BFM 2002: Protocol for the Treatment of Children With Relapsed Acute Lymphoblastic Leukemia Completed NCT00114348 Phase 4
32 LAL-Ph-2000: Treatment of Acute Lymphoblastic Leukemia Chromosome Philadelphia Positive Completed NCT00526305 Phase 4 Vincristine;Daunorubicin;Prednisone;L-Asparaginase;Mitoxantrone;Cytosine Arabinoside;Hydrocortisone;Mercaptopurine;Cyclophosphamide;Dexamethasone
33 LAL-BR/2001: Study Treatment to Low Risk ALL Completed NCT00526175 Phase 4 Prednisone;Vincristine;Daunorubicin;L-Asparaginase;Cyclophosphamide;Methotrexate;Cytosine Arabinoside;Mercaptopurine;VP-16
34 PETHEMA LAL-RI/96: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia Completed NCT00494897 Phase 4 Asparaginase;Cyclophosphamide;Cytarabine;Daunorubicin;Mercaptopurine;Prednisone;Vincristine;Methotrexate
35 LAL-AR-N-2005: Study Treatment for Children High Risk Acute Lymphoblastic Leukemia Completed NCT00526409 Phase 4 Prednisolone;Daunorubicin;Vincristine;L-Asparaginase;Cyclophosphamide;Methotrexate;Cytosine Arabinoside
36 Multicenter Trial for Treatment Optimization in T-lymphoblastic Lymphoma in Adults and Adolescents Older Than 15 Years (GMALL T-LBL 1/2004) (Amend 1) Completed NCT00199017 Phase 4 Dexamethasone/Prednisolone;Cyclophosphamide;Vincristine;Daunorubicin;Asparaginase;G-CSF;Mercaptopurine;Cytarabine;Methotrexate;VP16;Vindesine;Adriamycin;Thioguanine;HDARAC;Cladribine
37 The Effects of PROCRIT (Epoetin Alfa) on Hemoglobin, Symptom Distress, and Quality of Life During Chemotherapy in Lymphoma, Chronic Lymphocytic Leukemia or Multiple Myeloma Patients With Mild to Moderate Anemia Completed NCT00524407 Phase 4 Epoetin alfa
38 Multicenter Study to Optimise Therapy of B-ALL, Burkitt's NHL and High-Grade Non-Hodgkin's Lymphoma in Adults (Amend 7) Completed NCT00199082 Phase 4 Adriamycin;Cyclophosphamide;Cytarabine;Dexamethasone/Prednisolone;VP16;Ifosfamide;Methotrexate;G-CSF;Rituximab;Vincristine/Vindesine
39 Study Evaluating Rapid Infusion Rituximab in Patients With Autoimmune Diseases Completed NCT02040116 Phase 4 Rituximab Infusion
40 Busulfan Dose Escalation Study Based on AUC in the Setting of Busulfan/Fludarabine Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) Completed NCT00361140 Phase 4 Busulfan;Fludarabine
41 Alemtuzumab Versus Thymoglobulin Induction Therapy in Kidney and Pancreas Transplantation Completed NCT00331162 Phase 4 Alemtuzumab;Anti-Thymocyte Globulin
42 A Prospective, Multicenter, Open Label Single Arm Phase IV Clinical Trial to Assess Safety of ImbruvicaTM (Ibrutinib Capsules 140 mg) in Indian Patients With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion Recruiting NCT03190330 Phase 4 Ibrutinib 420 mg;Ibrutinib 560 mg
43 A PHASE 4, OPEN-LABEL, RANDOMIZED STUDY OF TWO INOTUZUMAB OZOGAMICIN DOSE LEVELS IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA ELIGIBLE FOR HEMATOPOIETIC STEM CELL TRANSPLANTATION AND WHO HAVE RISK FACTOR(S) FOR VENO-OCCLUSIVE DISEASE Recruiting NCT03677596 Phase 4 inotuzumab ozogamicin-dose level 2;Inotuzumab ozogamicin-dose level 1
44 Identification of New Immune Factors Specific of Relapse in Childhood B Lineage Acute Lymphoblastic Leukemia Recruiting NCT02618109 Phase 4
45 Plasma Kinetics of Tablet and Liquid Formulations of 6-mercaptopurine in Childhood Acute Lymphoblastic Leukemia. Recruiting NCT01906671 Phase 4 Xaluprine;Puri-Nethol
46 G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor: a Prospective, Multicentre, Randomised Controlled Trial Recruiting NCT02933333 Phase 4
47 Allogeneic Stem Cell Transplant for Children and Adolescents With Acute Lymoblastic Leukemia FORUM - Pharmacogenomic Study (add-on Study) Recruiting NCT02670564 Phase 4
48 PROTOCOL FOR THE TREATMENT Acute Lymphoblastic Leukemia With Ph 'NEGATIVE IN ELDERLY PATIENTS (> 55 Years) Recruiting NCT01366898 Phase 4 Dexamethasona, Idarubicine, ARA-C, Methotrexate
49 Chemotherapy and Imatinib in Young Adults With Acute Lymphoblastic Leukemia Ph (BCR-ABL) POSITIVE Recruiting NCT01491763 Phase 4 Imatinib
50 Treatment Protocol For All Fragile Patients Ph' Negative Over 55 Years Recruiting NCT01358201 Phase 4 vINCRISTINE;Dexamethasone;Methotrexate;Cytosine arabinoside

Search NIH Clinical Center for Lymphocytic Leukemia

Cochrane evidence based reviews: leukemia, lymphoid

Genetic Tests for Lymphocytic Leukemia

Anatomical Context for Lymphocytic Leukemia

MalaCards organs/tissues related to Lymphocytic Leukemia:

41
B Cells, T Cells, Bone, Bone Marrow, Myeloid, Testes, B Lymphoblasts

Publications for Lymphocytic Leukemia

Articles related to Lymphocytic Leukemia:

(show top 50) (show all 46146)
# Title Authors PMID Year
1
T-cell lymphoblastic leukemia in early childhood presents NOTCH1 mutations and MLL rearrangements. 9 38
19631984 2010
2
Wide diversity of PAX5 alterations in B-ALL: a Groupe Francophone de Cytogenetique Hematologique study. 9 38
20160164 2010
3
The role of glucocorticoid receptor phosphorylation in Mcl-1 and NOXA gene expression. 9 38
20156337 2010
4
Cytochemically myeloperoxidase positive childhood acute leukemia with lymphoblastic morphology treated as lymphoblastic leukemia. 9 38
19935430 2010
5
Telomere length, molecular cytogenetic findings, and immunophenotypic features in previously untreated patients with B-chronic lymphocytic leukemia. 9 38
20353271 2010
6
ABL1 gene deletion without BCR/ABL1 rearrangement in a young adolescent with precursor B-cell acute lymphoblastic leukemia: clinical study and literature review. 9 38
20082857 2010
7
Expression profiling of transcription factors in B- or T-acute lymphoblastic leukemia/lymphoma and burkitt lymphoma: usefulness of PAX5 immunostaining as pan-Pre-B-cell marker. 9 38
20023257 2010
8
Frequency and clinical relevance of DNA microsatellite alterations of the CDKN2A/B, ATM and p53 gene loci: a comparison between pediatric precursor T-cell lymphoblastic lymphoma and T-cell lymphoblastic leukemia. 9 38
19586936 2010
9
A novel translocation t(1;5)(p32;q31) that was not associated with the TAL1 rearrangement in a case of T lymphoblastic leukemia/lymphoma. 9 38
19571616 2009
10
Notch-1 regulates Akt signaling pathway and the expression of cell cycle regulatory proteins cyclin D1, CDK2 and p21 in T-ALL cell lines. 9 38
19091404 2009
11
Long-term culture of primary human lymphoblastic leukemia cells in the absence of serum or hematopoietic growth factors. 9 38
19135770 2009
12
CD38 as a prognostic factor in Chinese patients with chronic lymphocytic leukaemia. 9 38
18674817 2009
13
Prognostic relevance of serum levels and cellular expression of adiponectin in B-cell chronic lymphocytic leukemia. 9 38
18818986 2008
14
Construction, expression and in vitro biological effects of idiotype Ig Fab fragment of B-chronic lymphocytic leukemia. 9 38
18846324 2008
15
Ex vivo detection of primary leukemia cells resistant to granule cytotoxin-induced cell death: a rapid isolation method to study granzyme-B-mediated cell death. 9 38
18437383 2008
16
ZAP-70 is highly expressed in most cases of childhood pre-B cell acute lymphoblastic leukemia. 9 38
18333847 2008
17
ZAP-70 and CD38 expression are independent prognostic factors in patients with B-cell chronic lymphocytic leukaemia and combined analysis improves their predictive value. 9 38
18519230 2008
18
Hypermethylation of the p15INK4B gene promoter in B-chronic lymphocytic leukemia. 9 38
17546638 2007
19
[Bone marrow immunophenotypes of 112 cases of lymphoid system malignant diseases]. 9 38
17430665 2007
20
Development-dependent expression of cyclin D3 in precursor T-cell lymphoblastic leukemia/lymphoma. 9 38
17300668 2007
21
CD5 does not regulate the signaling triggered through BCR in B cells from a subset of B-CLL patients. 9 38
17325858 2007
22
Involvement of caspase-8 in chemotherapy-induced apoptosis of patient derived leukemia cell lines independent of the death receptor pathway and downstream from mitochondria. 9 38
17136321 2007
23
Pattern and distribution of immunoglobulin VH gene usage in a cohort of B-CLL patients from a Northeastern region of Italy. 9 38
17122648 2006
24
Expression levels of CD38 in T cells predict course of disease in male patients with B-chronic lymphocytic leukemia. 9 38
16825496 2006
25
Unscheduled CDK1 activity in G1 phase of the cell cycle triggers apoptosis in X-irradiated lymphocytic leukemia cells. 9 38
17013563 2006
26
NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth. 9 38
17114293 2006
27
B-chronic lymphocytic leukemia cells and other B cells can produce granzyme B and gain cytotoxic potential after interleukin-21-based activation. 9 38
16809616 2006
28
Aberrant stabilization of c-Myc protein in some lymphoblastic leukemias. 9 38
16855632 2006
29
Activating NOTCH1 mutations predict favorable early treatment response and long-term outcome in childhood precursor T-cell lymphoblastic leukemia. 9 38
16614245 2006
30
KIR ligands and prediction of relapse after unrelated donor hematopoietic cell transplantation for hematologic malignancy. 9 38
16864053 2006
31
CUTLL1, a novel human T-cell lymphoma cell line with t(7;9) rearrangement, aberrant NOTCH1 activation and high sensitivity to gamma-secretase inhibitors. 9 38
16688224 2006
32
Cellular FLICE-like inhibitory protein (c-FLIP): a novel target for Taxol-induced apoptosis. 9 38
16579975 2006
33
[ZAP-70 expression in 24 patients with B cell chronic lymphocytic leukemia]. 9 38
16638188 2006
34
Fludarabine induces apoptosis in chronic lymphocytic leukemia--the role of P53, Bcl-2, Bax, Mcl-1, and Bag-1 proteins. 9 38
16501812 2006
35
BCR-ABL1 induces aberrant splicing of IKAROS and lineage infidelity in pre-B lymphoblastic leukemia cells. 9 38
16205638 2006
36
11q22.3 deletion in B-chronic lymphocytic leukemia is specifically associated with bulky lymphadenopathy and ZAP-70 expression but not reduced expression of adhesion/cell surface receptor molecules. 9 38
16321852 2006
37
Involvement of SLP-65 and Btk in tumor suppression and malignant transformation of pre-B cells. 9 38
16300960 2006
38
Expression of heat-shock protein-90 in non-Hodgkin's lymphomas. 9 38
16056252 2005
39
Loss of Zap-70 and low molecular weight phosphotyrosine phosphatase occurs after therapy in a patient with B-chronic lymphocytic leukemia. 9 38
15931269 2005
40
Alterations of lymphoid enhancer factor-1 isoform expression in solid tumors and acute leukemias. 9 38
15756419 2005
41
A wide role for NOTCH1 signaling in acute leukemia. 9 38
15694671 2005
42
Taxol induces caspase-10-dependent apoptosis. 9 38
15452117 2004
43
Modulation of P-glycoprotein function by St John's wort extract and its major constituents. 9 38
15551196 2004
44
Lymphoblastic leukemia with mature B-cell phenotype in infancy. 9 38
15454841 2004
45
T-cell receptor-induced phosphorylation of the zeta chain is efficiently promoted by ZAP-70 but not Syk. 9 38
15059847 2004
46
LUCA-15/RBM5, a putative tumour suppressor, enhances multiple receptor-initiated death signals. 9 38
15192330 2004
47
Bcl-2 inhibitors sensitize tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by uncoupling of mitochondrial respiration in human leukemic CEM cells. 9 38
15150119 2004
48
Activation of the MDR1 upstream promoter in breast carcinoma as a surrogate for metastatic invasion. 9 38
15102684 2004
49
Cyclin D3 and c-MYC control glucocorticoid-induced cell cycle arrest but not apoptosis in lymphoblastic leukemia cells. 9 38
14576768 2004
50
Computer modeling and nanosecond simulation of the enzyme-substrate complex of the common lymphoblastic leukemia antigen (neprilysin) indicates shared residues at the primary specificity pocket (S1') with matrix metalloproteases. 9 38
14517614 2003

Variations for Lymphocytic Leukemia

Copy number variations for Lymphocytic Leukemia from CNVD:

7 (show top 50) (show all 117)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 15722 1 118792737 119283944 Deletion lymphocytic leukemia
2 28304 1 221094574 222727272 Deletion lymphocytic leukemia
3 29239 1 229351994 229691388 Deletion lymphocytic leukemia
4 35452 1 63608956 78245151 Deletion lymphocytic leukemia
5 37391 1 902529 3454889 Duplication lymphocytic leukemia
6 37447 1 912529 3454889 Duplication lymphocytic leukemia
7 37448 1 912529 3548139 Duplication lymphocytic leukemia
8 37449 1 912529 45151506 Deletion lymphocytic leukemia
9 37922 1 96795246 110397675 Deletion lymphocytic leukemia
10 42565 10 3607230 9585338 Duplication lymphocytic leukemia
11 48538 11 100299542 118463179 Deletion lymphocytic leukemia
12 48705 11 101900200 113746962 Deletion lymphocytic leukemia
13 54812 11 47479616 49590709 Deletion lymphocytic leukemia
14 54813 11 47479616 49590709 Deletion lymphocytic leukemia
15 55176 11 49408635 49590709 Deletion lymphocytic leukemia
16 58230 11 66842920 134431368 Duplication lymphocytic leukemia
17 59910 11 79505241 106371868 Deletion lymphocytic leukemia
18 59911 11 79505241 113746962 Deletion lymphocytic leukemia
19 60281 11 84811642 124583747 Deletion lymphocytic leukemia
20 60282 11 84811642 126916549 Deletion lymphocytic leukemia
21 60283 11 84811642 86481659 Deletion lymphocytic leukemia
22 60284 11 84811642 86481659 Deletion lymphocytic leukemia
23 60746 11 90634258 113746962 Deletion lymphocytic leukemia
24 60753 11 90736134 113746962 Deletion lymphocytic leukemia
25 63964 12 122218562 132289534 Deletion lymphocytic leukemia
26 65939 12 2267492 5164844 Duplication lymphocytic leukemia
27 72627 12 84097500 132289534 Deletion lymphocytic leukemia
28 75030 13 113525857 113954547 Duplication lymphocytic leukemia
29 77535 13 45167078 76782310 Deletion lymphocytic leukemia
30 77673 13 46386690 47967723 Deletion lymphocytic leukemia
31 77674 13 46386690 48065782 Deletion lymphocytic leukemia
32 77675 13 46386690 49406099 Deletion lymphocytic leukemia
33 77676 13 46386690 57242066 Deletion lymphocytic leukemia
34 77698 13 46660529 49406099 Deletion lymphocytic leukemia
35 77785 13 47624176 49406099 Deletion lymphocytic leukemia
36 77807 13 47759453 49406099 Deletion lymphocytic leukemia
37 78019 13 48903923 49406099 Deletion lymphocytic leukemia
38 82033 14 105267349 105437150 Deletion lymphocytic leukemia
39 82034 14 105267349 106339477 Deletion lymphocytic leukemia
40 87239 14 72506787 72834048 Deletion lymphocytic leukemia
41 88181 14 87377280 94457872 Deletion lymphocytic leukemia
42 91819 15 34882707 41330584 Deletion lymphocytic leukemia
43 98851 16 21509120 21698983 Deletion lymphocytic leukemia
44 106766 17 1 21055067 Copy number lymphocytic leukemia
45 106767 17 1 21055067 Deletion lymphocytic leukemia
46 106770 17 1 22098241 Deletion lymphocytic leukemia
47 108992 17 23775933 78654742 Copy number lymphocytic leukemia
48 108993 17 23775933 78654742 Duplication lymphocytic leukemia
49 113330 17 43041299 78654742 Duplication lymphocytic leukemia
50 119130 17 9926840 10302007 Duplication lymphocytic leukemia

Expression for Lymphocytic Leukemia

Search GEO for disease gene expression data for Lymphocytic Leukemia.

Pathways for Lymphocytic Leukemia

GO Terms for Lymphocytic Leukemia

Biological processes related to Lymphocytic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription, DNA-templated GO:0045893 9.83 TP53 TAL1 NOTCH1 MYC CD38
2 cell cycle arrest GO:0007050 9.46 TP53 NOTCH1 MYC ATM
3 positive regulation of endothelial cell differentiation GO:0045603 9.4 NOTCH1 BTG1
4 negative regulation of B cell proliferation GO:0030889 9.37 BTK ATM
5 left/right axis specification GO:0070986 9.32 SETDB2 NOTCH1
6 positive regulation of response to DNA damage stimulus GO:2001022 9.26 MYC ATM
7 response to gamma radiation GO:0010332 9.13 TRIM13 TP53 MYC
8 replicative senescence GO:0090399 8.8 TP53 MME ATM

Molecular functions related to Lymphocytic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein dimerization activity GO:0046983 8.92 TAL2 TAL1 MYC ATM

Sources for Lymphocytic Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....